Rheumatology (Oxford) doi:10.1093/rheumatology/kead089.
Real-world data from the PsABio study indicated that females with PsA had more severe disease than males before the initiation of treatment. While both genders experienced treatment related improvements, fewer females than males were able to achieve a favourable disease state within 12 months. Treatment discontinuation and switching were also higher in females than males, due to lower efficacy and adverse events.
While PsA has a similar prevalence across genders, there is currently a lack of data on gender-specific differences. However, previous rheumatological studies have consistently shown that gender may play a role in treatment efficacy and retention rates, with females exhibiting lower response rates and shorter treatment persistence periods. Future exploration of these differences, may allow for the development of improved therapeutic options for female patients.